ADAM17 cleaves the insulin receptor ectodomain on endothelial cells and causes vascular insulin resistance-Reference-Cited by-同舟云学术

ADAM17 cleaves the insulin receptor ectodomain on endothelial cells and causes vascular insulin resistance

Published:2022-10-01 Issue:4 Volume:323 Page:H688-H701
ISSN:0363-6135
Container-title:American Journal of Physiology-Heart and Circulatory Physiology
language:en
Short-container-title:American Journal of Physiology-Heart and Circulatory Physiology

Author:

Ghiarone Thaysa¹^ORCID,Castorena-Gonzalez Jorge A.²³,Foote Christopher A.¹,Ramirez-Perez Francisco I.¹⁴^ORCID,Ferreira-Santos Larissa¹^ORCID,Cabral-Amador Francisco J.¹,de la Torre Roger⁵,Ganga Rama R.⁶,Wheeler Andrew A.⁶^ORCID,Manrique-Acevedo Camila¹⁷⁸^ORCID,Padilla Jaume¹⁹^ORCID,Martinez-Lemus Luis A.¹²⁴^ORCID

Affiliation:

1. Dalton Cardiovascular Research Center, University of Missouri, Columbia, Missouri

2. Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, Missouri

3. Department of Pharmacology, School of Medicine, Tulane University, New Orleans, Louisiana

4. Department of Biomedical, Biological and Chemical Engineering, University of Missouri, Columbia, Missouri

5. HCA Healthcare, Kansas City, Missouri

6. Department of Surgery, University of Missouri, Columbia, Missouri

7. Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Missouri, Columbia, Missouri

8. Research Service, Harry S. Truman Memorial Veterans’ Hospital, Columbia, Missouri

9. Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, Missouri

Abstract

To our knowledge, this is the first study to investigate the involvement of ADAM17 in causing impaired insulin-induced vasodilation in T2D. We provide evidence that ADAM17 activity is increased in the vasculature of patients with T2D and support the notion that ADAM17-mediated shedding of endothelial IRα ectodomains is a novel mechanism causing vascular insulin resistance. Our results highlight that targeting ADAM17 activity may be a potential therapeutic strategy to correct vascular insulin resistance in T2D.

Funder

HHS | NIH | National Heart, Lung, and Blood Institute

Publisher

American Physiological Society

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine,Physiology

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpheart.00039.2022

Reference67 articles.

1. Prevalence of Diabetes and Prediabetes according to Fasting Plasma Glucose and HbA1c

2. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, 2017.

3. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity

4. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence

5. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuraminidase-induced externalization of phosphatidylserine activates ADAM17 and impairs insulin signaling in endothelial cells;American Journal of Physiology-Heart and Circulatory Physiology;2024-01-01

2. Diabetic Endothelial Cell Glycogen Synthase Kinase 3β Activation Induces VCAM1 Ectodomain Shedding;International Journal of Molecular Sciences;2023-09-14

3. New insights into mechanisms of endothelial insulin resistance in type 2 diabetes;American Journal of Physiology-Heart and Circulatory Physiology;2022-12-01